Innovotech

Innovotech Current Assets

Current Assets of Innovotech (IOT.V) as of Nov 20, 2026.

Current Assets

-CAD

Last updated:

Current Assets of Innovotech is 2026 - CAD. Current Assets of Innovotech was 2025 - CAD. It decreases by % lower compared to the previous year.

The Innovotech Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2006
440,000.00 CAD
Jan 1, 2007
2.39 M CAD
Jan 1, 2008
2.43 M CAD
Jan 1, 2009
2.00 M CAD
Jan 1, 2010
1.14 M CAD
Jan 1, 2011
980,000.00 CAD
Jan 1, 2012
700,000.00 CAD
The Innovotech Current Assets history
YEARCurrent AssetsYoY
700,000.00CAD-28.57%
980,000.00CAD-14.04%
1.14 MCAD-43.00%
2.00 MCAD-17.70%
2.43 MCAD+1.67%
2.39 MCAD+443.18%
440,000.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innovotech Stock analysis

What does Innovotech do? Innovotech Inc. generates revenue through the sale of proprietary assay kits, including MBEC Assay Kits, Order Biofilm Assays, and Coated MBEC Assay Lids, which are used in microbial biofilm research. The company also provides contract research services such as Antimicrobial Contract Research, Antimicrobial and Anti-Biofilm Agents testing (MIC and MBEC), and Customized Antimicrobial Testing (BEST Assay Testing and Implanted Medical Device Testing). Its antimicrobial silver products, AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products, are sold to customers in agricultural and medical sectors. The firm targets research institutions, agricultural producers, and medical device manufacturers seeking biofilm and antimicrobial testing solutions. Innovotech's intellectual property portfolio supports its contract research services, which include testing for antimicrobial agents and materials under standards like TM100, ISO 22196, and USP 51. The company’s Biofilm Publications and SEM Library serve as additional resources for clients engaged in biofilm research. Its product offerings are tailored to sectors requiring microbial biofilm analysis, such as crop protection and medical device development, with AgreGuard-1 and InnovoSIL products specifically addressing antimicrobial needs in agriculture and medical applications. The company monetizes its proprietary technology through direct sales of assay kits and antimicrobial silver products, while contract research services provide recurring revenue streams. Clients include research organizations conducting biofilm studies, agricultural businesses using AgreGuard-1 for crop protection, and medical device manufacturers utilizing InnovoSIL for antimicrobial properties. Innovotech’s focus on specialized testing methodologies and branded products ensures consistent demand from niche markets requiring precise biofilm and antimicrobial evaluation. Innovotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innovotech stock

On Eulerpool you can find the complete historical development of Current Assets Innovotech since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Innovotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Innovotech

All Key Metrics — Innovotech